NewsBytes
    Hindi Tamil Telugu
    More
    In the news
    Supreme Court Of India
    Central Bureau Of Investigation (CBI)
    Indian Army
    Indian Railways
    Indian Air Force
    NewsBytes
    Hindi Tamil Telugu
    NewsBytes
    User Placeholder

    Hi,

    Logout


    India Business World Politics Sports Technology Entertainment Auto Lifestyle Inspirational Career Bengaluru Delhi Mumbai Visual Stories Find Cricket Statistics Phones Reviews Fitness Bands Reviews Speakers Reviews

    Download Android App

    Follow us on
    • Facebook
    • Twitter
    • Linkedin
     
    Home / News / India News / AIIMS to submit proposal for COVAXIN's phase three trials soon
    India

    AIIMS to submit proposal for COVAXIN's phase three trials soon

    AIIMS to submit proposal for COVAXIN's phase three trials soon
    Written by Shalini Ojha
    Oct 31, 2020, 08:40 pm 2 min read
    AIIMS to submit proposal for COVAXIN's phase three trials soon

    By early next week, AIIMS will submit a proposal to start the third phase of clinical trials of COVAXIN, a vaccine against coronavirus being developed by Bharat Biotech. The Drugs Controller General of India has last week given approval to the company to conduct the phase three trials of its potential vaccine. AIIMS is one of the sites selected for the trials. Here's more.

    Proposal is being prepared, confirmed AIIMS official

    Dr. Sanjay Rai, professor, department of community medicine, AIIMS Delhi, confirmed to HT that the plan related to COVAXIN is in the works. "The proposal is being prepared for the phase three trials, and within a couple of days we will be submitting it to the institute ethics committee for approval," he said. Unless the institute ethics committee gives a clearance, trials can't commence.

    Proposal will be 200-300 pages long: Dr. Rai

    Dr. Rai revealed that the proposal will run into 200-300 pages. "The idea is to review and look for gaps, if any, that would address all concerns. The concerns that are usually raised almost always are valid, which you might miss otherwise. It helps," he added. For the earlier phases, Dr. Rai's team submitted proposals on June 30 and got approvals on July 18.

    No safety concerns raised after phase one of trials

    After phase one trials, no safety concerns were raised about COVAXIN. The safety test for phase two has been finished, while the immunogenicity test, to judge the body's response to the vaccine, is underway, said the daily. For phase three, Bharat Biotech hopes to recruit 26,000 participants across 25-30 hospital sites in 13-14 states. AIIMS is planning to test the vaccine on 2,000-5,000 participants.

    COVAXIN uses an inactivated SARS-CoV-2 virus

    Bharat Biotech has partnered with the National Institute of Virology, one of the translational science cells of ICMR. The potential vaccine uses an inactivated SARS-CoV-2 virus and would require two doses, to be administered within a gap of 14 days. COVAXIN is India's first vaccine candidate. Naturally, the success of the phase three trials will determine the efficiency of the vaccine.

    Share this timeline
    Facebook
    Whatsapp
    Twitter
    Linkedin
    Latest
    India
    All India Institute Of Medical Sciences (AIIMS)
    Drugs Controller General of India
    Coronavirus

    Latest

    Is 2023 Hyundai VERNA better than 2023 Honda City Hyundai Verna
    Virat Kohli smashes his 65th ODI half-century, leaves behind legends Virat Kohli
    Australia beat India in 3rd ODI, seal series 2-1: Stats  India vs Australia Cricket
    Suryakumar Yadav registers third consecutive golden duck (ODIs): Key stats Suryakumar Yadav

    India

    The world now has fewer billionaires: Here's what happened USA
    India reports highest daily COVID-19 cases in 2023: Check tally COVID-19 India
    6.6 magnitude quake in Afghanistan, tremors felt in North India  Earthquake
    India witnessed significant human rights violations in 2022: US report United States of America

    All India Institute Of Medical Sciences (AIIMS)

    Delhi: Woman's skull, chopped body parts found in polythene bag Delhi
    Delhi's crucial Ashram Flyover reopened: All you need to know Delhi
    Another Delhi shocker: Woman set ablaze by live-in partner dies Delhi
    Shraddha Walkar murder: Police's 3000-draft chargesheet ready, legal approval awaited Shraddha Walkar

    Drugs Controller General of India

    Serum Institute seeks DCGI's approval for Covovax as booster dose Serum Institute of India
    Lumpy skin disease kills 67,000 cattle across India: Details here Narendra Modi
    Clinical trials for nasal COVID-19 vaccine complete: Bharat Biotech World Health Organization
    DCGI clears COVAXIN, Corbevax for children aged 6-12, 5-12 years COVID-19 Vaccine

    Coronavirus

    PM Modi to hold high-level meeting amid rising COVID-19 cases Narendra Modi
    COVID-19 subvariant XBB 1.16 cases rise in India; guidelines revised COVID-19
    WHO lambasts China for allegedly hiding data on COVID-19's origin World Health Organization
    India records over 800 daily COVID-19 cases after 126 days COVID-19

    Love India News?

    Subscribe to stay updated.

    India Thumbnail
    Indian Premier League (IPL) Celebrity Hollywood Bollywood UEFA Champions League Tennis Football Smartphones Cryptocurrency Upcoming Movies Premier League Cricket News Latest automobiles Latest Cars Upcoming Cars Latest Bikes Upcoming Tablets
    About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive Download DevBytes Find Cricket Statistics
    Follow us on
    Facebook Twitter Linkedin
    All rights reserved © NewsBytes 2023